Patents Assigned to Bolder Biotechnology, Inc.
  • Patent number: 10329337
    Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: June 25, 2019
    Assignee: BOLDER BIOTECHNOLOGY, INC.
    Inventor: George N. Cox
  • Patent number: 10016485
    Abstract: Methods and compositions for the use of long-acting hematopoietic factor protein analogs for accelerating hematopoietic recovery in subjects who have been or will be exposed to radiation are disclosed.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 10, 2018
    Assignee: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Christie M. Orschell
  • Patent number: 9637530
    Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: May 2, 2017
    Assignee: Bolder Biotechnology, Inc.
    Inventor: George N. Cox, III
  • Publication number: 20160200790
    Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.
    Type: Application
    Filed: April 25, 2014
    Publication date: July 14, 2016
    Applicant: BOLDER BIOTECHNOLOGY, INC.
    Inventor: George N. Cox, III
  • Patent number: 9320777
    Abstract: Methods and compositions for the use of long-acting hematopoietic factor protein analogs for accelerating hematopoietic recovery in subjects who have been or will be exposed to radiation are disclosed.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: April 26, 2016
    Assignee: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Christie M. Orschell
  • Patent number: 9296804
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: March 29, 2016
    Assignee: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Mary S. Rosendahl
  • Patent number: 8957023
    Abstract: The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 17, 2015
    Assignee: Bolder Biotechnology Inc.
    Inventor: George N. Cox
  • Publication number: 20150023918
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Application
    Filed: November 25, 2013
    Publication date: January 22, 2015
    Applicant: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Mary S. Rosendahl
  • Patent number: 8932828
    Abstract: The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: January 13, 2015
    Assignee: Bolder Biotechnology, Inc.
    Inventors: Mary S. Rosendahl, George N. Cox, Daniel H. Doherty
  • Patent number: 8859497
    Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: October 14, 2014
    Assignee: Bolder BioTechnology, Inc.
    Inventor: George N. Cox
  • Publication number: 20140163204
    Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.
    Type: Application
    Filed: November 25, 2013
    Publication date: June 12, 2014
    Applicant: Bolder Biotechnology, Inc.
    Inventor: George N. Cox
  • Patent number: 8748392
    Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: June 10, 2014
    Assignee: Bolder BioTechnology Inc.
    Inventor: George N. Cox, III
  • Patent number: 8617531
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: December 31, 2013
    Assignee: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Mary S. Rosendahl
  • Publication number: 20130217629
    Abstract: The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 22, 2013
    Applicant: BOLDER BIOTECHNOLOGY, INC.
    Inventors: George N. Cox, Daniel H. Doherty, Mary S. Rosendahl
  • Patent number: 8455434
    Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: June 4, 2013
    Assignee: Bolder Biotechnology, Inc.
    Inventor: George N. Cox
  • Patent number: 8329866
    Abstract: Disclosed are polymer sFlt-1 conjugates, variants of sFlt-1, compositions comprising such conjugates and variants, including cysteine variants of sFlt-1. Also disclosed is the use of such conjugates, variants and compositions in methods to inhibit the activity of VEGF, to inhibit angiogenesis, and to treat or reduce at least one symptom of diseases and conditions in which it is desirable to inhibit VEGF activity and/or angiogenesis.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: December 11, 2012
    Assignee: Bolder Biotechnology, Inc.
    Inventors: Mary S. Rosendahl, George N. Cox, III
  • Patent number: 8288126
    Abstract: The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: October 16, 2012
    Assignee: Bolder BioTechnology, Inc.
    Inventors: George N. Cox, Daniel H. Doherty, Mary S. Rosendahl
  • Publication number: 20120231040
    Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.
    Type: Application
    Filed: February 2, 2012
    Publication date: September 13, 2012
    Applicant: BOLDER BIOTECHNOLOGY, INC.
    Inventor: George N. Cox, III
  • Patent number: 8148500
    Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: April 3, 2012
    Assignee: Bolder BioTechnology, Inc.
    Inventors: George N. Cox, III, Daniel H. Doherty
  • Patent number: 8133480
    Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: March 13, 2012
    Assignee: Bolder Biotechnology, Inc.
    Inventor: George N. Cox, III